（08.23 --08.29/ 2010）
美寶國際集團(tuán):陶國新 

　　本周動(dòng)態(tài)包括以下內(nèi)容： 體內(nèi)葡萄糖含量過高影響免疫系統(tǒng) ; MIT 科學(xué)家發(fā)明人類干細(xì)胞培養(yǎng)新方法； 骨髓移植治療 大皰性表皮松解癥； 生物合成角膜有助視力恢復(fù)；科學(xué)家 確認(rèn)血脂代謝相關(guān)基因座 。

•  體內(nèi)葡萄糖含量過高影響免疫系統(tǒng)
【摘要】 來源：科技日?qǐng)?bào) 發(fā)布時(shí)間： 2010-8-27 17:13:23

　　糖尿病患者除易患腎臟疾病等并發(fā)癥外，也很容易被慢性細(xì)菌和真菌感染而患上炎癥性疾病。對(duì)于這類并發(fā)癥的病理機(jī)制，醫(yī)學(xué)界一直不太清楚。英國華威大學(xué)最新研究表明，這是由于人體內(nèi)葡萄糖水平過高影響了免疫系統(tǒng)，抑制其功能發(fā)揮造成的。華威大學(xué) 8 月 25 日發(fā)布的公報(bào)中稱，該校研究人員對(duì)人體血液和體液中的葡萄糖和另外兩種糖——甘露糖和巖藻糖的化學(xué)結(jié)構(gòu)進(jìn)行了分析。甘露糖和巖藻糖是人體免疫受體識(shí)別細(xì)菌和真菌的標(biāo)記，免疫受體會(huì)與這兩種微糖綁定來對(duì)抗感染。研究人員發(fā)現(xiàn)，人體內(nèi)葡萄糖水平一旦過高，其就會(huì)代替甘露糖和巖藻糖綁定免疫受體，從而妨礙免疫受體識(shí)別感染性細(xì)菌和真菌。這種越俎代庖的行為，會(huì)抑制人體對(duì)抗感染的正常進(jìn)程。它會(huì)抑制人體免疫系統(tǒng) C 型凝集素的功能。這些凝集素中，包括甘露糖結(jié)合凝集素（ MBL ），其功能失效，則會(huì)使人更易患上炎癥性疾病；它也會(huì)影響免疫細(xì)胞表面受體 DC-SIGN 和 DC-SIGNR ，這兩種受體存在于白血球、血小板、血管內(nèi)皮細(xì)胞等循環(huán)和血管系統(tǒng)的關(guān)鍵部位中，它們的功能受到抑制，則會(huì)導(dǎo)致糖尿病人出現(xiàn)心血管和腎臟并發(fā)癥。  

　　華威大學(xué)醫(yī)學(xué)院的丹尼爾· 米切爾 博士表示，葡萄糖水平與人體免疫系統(tǒng)之間的這種關(guān)系，使科學(xué)家對(duì)高葡萄糖對(duì)免疫系統(tǒng)和身體健康的影響有了新的認(rèn)識(shí)。而日常生活中保持合理的飲食結(jié)構(gòu)，控制血糖水平則更顯得重要。他們將基于新發(fā)現(xiàn)來完善糖尿病疾病模型，以尋找新的防治手段。

【點(diǎn)評(píng)】

　　該項(xiàng)研究發(fā)現(xiàn)了人體內(nèi) 高水平葡萄糖會(huì)通過競(jìng)爭(zhēng)性抑制來干擾免疫受體對(duì)寡糖的體識(shí)，進(jìn)而妨礙免疫受體識(shí)別感染性細(xì)菌和真菌，抑制人體對(duì)抗感染的正常進(jìn)程。對(duì)于人類，尤其是糖尿病人，重新認(rèn)識(shí)高血糖的生理意義及其對(duì)糖尿病并發(fā)癥的作用有重要影響。同時(shí)也提醒人們?nèi)粘ｏ嬍硵z入過多的糖分很可能會(huì)降低你的身體免疫力。

【原文摘錄 】   Immunobiology doi:10.1016/j.imbio.2010.06.002 

High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitus.

Ilyas R , Wallis R , Soilleux EJ , et al.

Diabetic complications include infection and cardiovascular disease. Within the immune system, host-pathogen and regulatory host-host interactions operate through binding of oligosaccharides by C-type lectin. A number of C-type lectins recognise oligosaccharides rich in mannose and fucose - sugars with similar structures to glucose. This raises the possibility that high glucose conditions in diabetes affect protein-oligosaccharide interactions via competitive inhibition. Mannose-binding lectin, soluble DC-SIGN and DC-SIGNR, and surfactant protein D, were tested for carbohydrate binding in the presence of glucose concentrations typical of diabetes, via surface plasmon resonance and affinity chromatography. Complement activation assays were performed in high glucose. DC-SIGN and DC-SIGNR expression in adipose tissues was examined via immunohistochemistry. High glucose inhibited C-type lectin binding to high-mannose glycoprotein and binding of DC-SIGN to fucosylated ligand (blood group B) was abrogated in high glucose. Complement activation via the lectin pathway was inhibited in high glucose and also in high trehalose - a nonreducing sugar with glucoside stereochemistry. DC-SIGN staining was seen on cells with DC morphology within omental and subcutaneous adipose tissues. We conclude that high glucose disrupts C-type lectin function, potentially illuminating new perspectives on susceptibility to infectious and inflammatory disease in diabetes. Mechanisms involve competitive inhibition of carbohydrate binding within sets of defined proteins, in contrast to broadly indiscriminate, irreversible glycation of proteins.

•  MIT 科學(xué)家發(fā)明人類干細(xì)胞培養(yǎng)新方法

【摘要】

　　多功能干細(xì)胞能夠分化成其他任何一種體細(xì)胞，在治療各種疾病方面具有很大潛力。但是，如何培養(yǎng)足夠量的多功能干細(xì)胞對(duì)研究者來說是個(gè)問題；此外，目前用于培養(yǎng)人類干細(xì)胞的材料會(huì)導(dǎo)致免疫反應(yīng)。為了克服這些問題，以美國麻省理工學(xué)院（ MIT ）科學(xué)家為首的研究小組發(fā)明了一種合成性基質(zhì)（ synthetic substrate ）。這種基質(zhì)沒有外來動(dòng)物材料，能夠使干細(xì)胞至少三個(gè)月保持活性并自我繁殖。而且，該合成性基質(zhì)首次使得單細(xì)胞能夠形成細(xì)胞集落。相關(guān)研究發(fā)表在 8 月 22 日的《自然—材料學(xué)》（ Nature Materials ）上。

　　以往研究表明，基質(zhì)表面的化學(xué)和物理特性，比如粗糙度、硬度、對(duì)水的親和力等對(duì)干細(xì)胞生長有影響。 MIT 研究人員創(chuàng)造了 500 種特性不同的聚合物并在上面培養(yǎng)干細(xì)胞，分析每個(gè)聚合物上面細(xì)胞的生長狀況。他們發(fā)現(xiàn)， 基質(zhì)表面疏水性 對(duì)細(xì)胞生長有個(gè)最佳范圍，而表面糙度和硬度則沒有太多影響。此外，他們調(diào)整最佳聚合物的組成為：高比例的丙烯酸酯，外面包裹玻連蛋白。應(yīng)用這種新的培養(yǎng)基質(zhì)， MIT 科學(xué)家成功實(shí)現(xiàn)了人類胚胎干細(xì)胞持續(xù)三個(gè)月的生長和分裂，并獲得了大量的細(xì)胞。他們將進(jìn)一步研究，爭(zhēng)取將這種培養(yǎng)基質(zhì)應(yīng)用到其它類細(xì)胞。（ 來源： 科學(xué)網(wǎng) www.sciencenet.cn 發(fā)布時(shí)間： 2010-8-24 10:43:34 ）

【點(diǎn)評(píng)】

　　新的培養(yǎng)基質(zhì)可以使干細(xì)胞長時(shí)間保持活性和自我繁殖，對(duì)于解決干細(xì)胞研究中獲取大量干細(xì)胞的問題有很大幫助。雖然不能因此使干細(xì)胞治療有實(shí)質(zhì)性進(jìn)展，但至少有助于干細(xì)胞的實(shí)驗(yàn)研究。

【原文摘錄】 Nature Materials 9, 768–778 doi:10.1038/nmat2812

Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells

Ying Mei , Krishanu Saha , Said R. Bogatyrev ， et al.

Both human embryonic stem cells and induced pluripotent stem cells can self-renew indefinitely in culture; however, present methods to clonally grow them are inefficient and poorly defined for genetic manipulation and therapeutic purposes. Here we develop the first chemically defined, xeno-free, feeder-free synthetic substrates to support robust self-renewal of fully dissociated human embryonic stem and induced pluripotent stem cells. Material properties including wettability, surface topography, surface chemistry and indentation elastic modulus of all polymeric substrates were quantified using high-throughput methods to develop structure–function relationships between material properties and biological performance. These analyses show that optimal human embryonic stem cell substrates are generated from monomers with high acrylate content, have a moderate wettability and employ integrin α v β 3 and α v β 5 engagement with adsorbed vitronectin to promote colony formation. The structure–function methodology employed herein provides a general framework for the combinatorial development of synthetic substrates for stem cell culture.

•  骨髓移植治療 大皰性表皮松解癥
【摘要】 NEJM 發(fā)布時(shí)間： 2010-8-25 15:33:04

　　大皰性表皮松解癥是由于皮膚結(jié)構(gòu)蛋白的先天性缺陷，使皮膚容易發(fā)生松解出現(xiàn)大皰。如單純性大皰性表皮松解癥是由于表皮基底細(xì)胞的結(jié)構(gòu)蛋白 -- 角蛋白 5 或角蛋白 14 的缺陷所致；交界性大皰性表皮松解癥是由于 BPAG2 或板素 (Laminin)5 的缺陷所致；營養(yǎng)不良型大皰性表皮松解癥則是由于基底膜帶中 Ⅶ 型膠原蛋白的缺陷所致?，F(xiàn)已弄清缺陷的發(fā)生是因?yàn)檫@些編碼蛋白的基因出現(xiàn)了突變，導(dǎo)致蛋白質(zhì)的結(jié)構(gòu)異常，使皮膚松解。盡管遺傳學(xué)基礎(chǔ)已被闡明，但仍無有效的治療。大皰性表皮松解的治療主要針對(duì)其繼發(fā)感染，原則為精心護(hù)理，保護(hù)局部，避免外傷、摩擦受熱防止繼發(fā)感染。利用干細(xì)胞產(chǎn)生新的組織和器官，修復(fù)破損的組織、器官，被稱為再生醫(yī)學(xué)。 美國《新英格蘭醫(yī)學(xué)雜志》（ NEJM ） 8 月 11 日刊登明尼蘇達(dá)大學(xué)研究者約翰· 瓦格納和雅各布·托拉爾的研究報(bào)告，首次顯示骨髓干細(xì)胞可用于治療營養(yǎng)不良型大皰性表皮松解癥，為根除這一頑疾帶來了希望。

【點(diǎn)評(píng)】

　　用于 6 名大皰性表皮松解癥患者的同種異體骨髓移植的實(shí)驗(yàn)性臨床治療為從根本上治愈這一頑癥提供了一種可能，盡管這一方法的長期風(fēng)險(xiǎn)和效果還有待進(jìn)一步評(píng)估。另一方面，該研究也提示該治療中骨髓干細(xì)胞可能是分化成正常皮膚組織的來源。

【原文摘錄 】 N Engl J Med 2010; 363:629-639 August 12, 2010

Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa

John E. Wagner, M.D., Akemi Ishida-Yamamoto, M.D., Ph.D., John A. McGrath, M.D., et al.

Background

Recessive dystrophic epidermolysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in COL 7A 1, the gene encoding type VII collagen (C7). On the basis of preclinical data showing biochemical correction and prolonged survival in col7 −/− mice, we hypothesized that allogeneic marrow contains stem cells capable of ameliorating the manifestations of recessive dystrophic epidermolysis bullosa in humans.

Methods

Between October 2007 and August 2009, we treated seven children who had recessive dystrophic epidermolysis bullosa with immunomyeloablative chemotherapy and allogeneic stem-cell transplantation. We assessed C7 expression by means of immunofluorescence staining and used transmission electron microscopy to visualize anchoring fibrils. We measured chimerism by means of competitive polymerase-chain-reaction assay, and documented blister formation and wound healing with the use of digital photography.

Results

One patient died of cardiomyopathy before transplantation. Of the remaining six patients, one had severe regimen-related cutaneous toxicity, with all having improved wound healing and a reduction in blister formation between 30 and 130 days after transplantation. We observed increased C7 deposition at the dermal–epidermal junction in five of the six recipients, albeit without normalization of anchoring fibrils. Five recipients were alive 130 to 799 days after transplantation; one died at 183 days as a consequence of graft rejection and infection. The six recipients had substantial proportions of donor cells in the skin, and none had detectable anti-C7 antibodies.

Conclusions

Increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation. Further studies are needed to assess the long-term risks and benefits of such therapy in patients with this disorder.

•  生物合成角膜有助視力恢復(fù)
【摘要】 來源：《科學(xué)—轉(zhuǎn)化醫(yī)學(xué)》 發(fā)布時(shí)間： 2010-8-27 16:22:22

　　加拿大和瑞典科研人員研制出一種生物合成角膜，幫助眼疾患者修復(fù)受損眼組織，恢復(fù)視力。由加拿大渥太華醫(yī)院研究所研究員梅·格里菲思和瑞典林雪平大學(xué)眼科學(xué)教授佩爾·法格霍爾姆領(lǐng)導(dǎo)的一個(gè)研究小組將 10 名患者角膜中的受損組織移除后，植入人造角膜。術(shù)后，研究人員經(jīng)過兩年多的跟蹤觀察，發(fā)現(xiàn)其中 9 名患者的人造角膜與眼球其他細(xì)胞融合。研究人員說，接受移植后的眼球開始分泌淚液。 6 名患者的視力逐漸恢復(fù)。“這項(xiàng)研究第一次表明，人造角膜可以與人的眼球融合并激發(fā)組織再生 , ”格里菲斯說：“隨著研究的深入，這種方式能幫助數(shù)以百萬計(jì)等待角膜移植的人恢復(fù)視力?！苯悄な茄矍虮砻娓采w的一層透明、膠片狀組織，主要成分是蛋白膠原質(zhì)，能夠折射光線，將景物成像于視網(wǎng)膜上。盡管角膜容易受到外傷或感染而受損，但眼下的醫(yī)學(xué)技術(shù)能夠通過角膜移植手術(shù)令患者恢復(fù)視力。研究人員說，由于眼角膜捐獻(xiàn)數(shù)量有限，全球每年有許多人因角膜受傷致殘。他們這項(xiàng)研究成果有助于這些眼疾患者重見光明。

【點(diǎn)評(píng)】

　　兩年多跟蹤觀察 10 名移植了人造角膜的患者， 9 名患者的人造角膜與眼球其他細(xì)胞融合， 6 名患者的視力逐漸恢復(fù)。長期效果有待觀察，但這項(xiàng)研究第一次表明，人造角膜可以與人的眼球融合并激發(fā)組織再生，有可能幫助因角膜受傷致殘患者重見光明。在醫(yī)用材料而言是一大突破。

【原文摘錄 】 Sci Transl Med Vol. 2, Issue 46, p. 46ra61 DOI: 10.1126/scitranslmed.3001022

A Biosynthetic Alternative to Human Donor Tissue for Inducing Corneal Regeneration: 24-Month Follow-Up of a Phase 1 Clinical Study

Per Fagerholm , Neil S. Lagali , Kimberley Merrett , et al.

Corneas from human donors are used to replace damaged tissue and treat corneal blindness, but there is a severe worldwide shortage of donor corneas. We conducted a phase 1 clinical study in which biosynthetic mimics of corneal extracellular matrix were implanted to replace the pathologic anterior cornea of 10 patients who had significant vision loss, with the aim of facilitating endogenous tissue regeneration without the use of human donor tissue. The biosynthetic implants remained stably integrated and avascular for 24 months after surgery, without the need for long-term use of the steroid immunosuppression that is required for traditional allotransplantation. Corneal reepithelialization occurred in all patients, although a delay in epithelial closure as a result of the overlying retaining sutures led to early, localized implant thinning and fibrosis in some patients. The tear film was restored, and stromal cells were recruited into the implant in all patients. Nerve regeneration was also observed and touch sensitivity was restored, both to an equal or to a greater degree than is seen with human donor tissue. Vision at 24 months improved from preoperative values in six patients. With further optimization, biosynthetic corneal implants could offer a safe and effective alternative to the implantation of human tissue to help address the current donor cornea shortage.

•  科學(xué)家確認(rèn)血脂代謝相關(guān)基因座
【摘要】 《自然》 發(fā)布時(shí)間： 2010-8-25 17:47:46

　　血液中總膽固醇、低密度脂蛋白膽固醇、高密度脂蛋白膽固醇和甘油三酯等脂類含量是導(dǎo)致冠狀動(dòng)脈疾?。?CAD ）的最重要危險(xiǎn)因素，同時(shí)也是防治該種疾病的重要標(biāo)靶。一國際研究小組在《自然》（ Nature ）雜志上刊登報(bào)告稱，他們研究確認(rèn)了 95 個(gè)與人類血脂代謝相關(guān)的基因座，可作為冠狀動(dòng)脈疾病的生物學(xué)標(biāo)記。研究人員稱，新研究不僅擴(kuò)展了科學(xué)家對(duì)人體脂類代謝的理解視野，同時(shí)也為開發(fā)新型防治冠狀動(dòng)脈疾病的靶向型藥物奠定了基礎(chǔ)。 該國際研究小組由英美等多國近百位科學(xué)家組成，他們對(duì)超過 10 萬名具有歐洲血統(tǒng)的志愿者的基因進(jìn)行了分析，最終確認(rèn)了 95 個(gè)與脂類代謝相關(guān)的基因座，其中有 59 個(gè)基因座是首次被認(rèn)定。這 95 個(gè)基因座不僅會(huì)導(dǎo)致人體內(nèi)脂類特性的一般性改變，而且還會(huì)導(dǎo)致極端的脂類表型。研究結(jié)果表明，一些新發(fā)現(xiàn)的基因座與冠狀動(dòng)脈疾病有關(guān)。研究人員還就 GALNT2 、 PPP1R3B 和 TTC39B 這三種新基因在小鼠模型上進(jìn)行了驗(yàn)證。  

　　研究人員表示，此項(xiàng)研究是目前就人體脂類代謝機(jī)制生物學(xué)基礎(chǔ)問題所進(jìn)行的最全面的分析研究，其目的是要找到血液中脂類聚集的生物學(xué)標(biāo)記，以作為冠狀動(dòng)脈疾病發(fā)展的指標(biāo)。研究結(jié)果則表明，通過抑制這些與脂類代謝有關(guān)的關(guān)鍵基因，可以起到預(yù)防心臟疾病的作用，這為開發(fā)新的靶向型藥物提供了基礎(chǔ)。英國倫敦國王大學(xué)的馬西莫·曼 吉諾 博士指出，這項(xiàng)研究對(duì)于科學(xué)家掌握冠狀動(dòng)脈疾病的風(fēng)險(xiǎn)因素很有幫助。雖然研究對(duì)象是具有歐洲血統(tǒng)的志愿者，但研究人員發(fā)現(xiàn)，這些基因座并非歐洲人獨(dú)有，其對(duì)三個(gè)非歐洲人群體（東亞人、南亞人以及非洲裔美國人）的脂類特性也會(huì)產(chǎn)生重要影響。作為此方面迄今為止最大規(guī)模的研究，超大的樣本量使得該結(jié)果同樣具有國際意義。（來源：科技日?qǐng)?bào) 劉海英 / 劉霞）

【點(diǎn)評(píng)】

　　作為就人體脂類代謝機(jī)制生物學(xué)基礎(chǔ)問題所進(jìn)行超大樣本量的最全面的分析研究，對(duì)于科學(xué)家掌握冠狀動(dòng)脈疾病的風(fēng)險(xiǎn)因素很有幫助。但是否因此就能發(fā)展出更好的治療冠狀動(dòng)脈疾病的療法或藥物還看不出來。

【原文摘錄 】 Nature doi:10.1038/nature09270
Biological, clinical and population relevance of 95 loci for blood lipids

Tanya M. Teslovich , Kiran Musunuru , Albert V. Smith , et al.

Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides are among the most important risk factors for coronary artery disease (CAD) and are targets for therapeutic intervention. We screened the genome for common variants associated with plasma lipids in >100,000 individuals of European ancestry. Here we report 95 significantly associated loci ( P < 5 × 10 −8 ), with 59 showing genome-wide significant association with lipid traits for the first time. The newly reported associations include single nucleotide polymorphisms (SNPs) near known lipid regulators (for example, CYP 7A 1 , NPC 1L 1 and SCARB1 ) as well as in scores of loci not previously implicated in lipoprotein metabolism. The 95 loci contribute not only to normal variation in lipid traits but also to extreme lipid phenotypes and have an impact on lipid traits in three non-European populations (East Asians, South Asians and African Americans). Our results identify several novel loci associated with plasma lipids that are also associated with CAD. Finally, we validated three of the novel genes— GALNT2 , PPP1R3B and TTC39B —with experiments in mouse models. Taken together, our findings provide the foundation to develop a broader biological understanding of lipoprotein metabolism and to identify new therapeutic opportunities for the prevention of CAD.